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Abstract
Introduction Antitumour activity is one of the health-promoting
effects attributed to the lactic acid bacteria and their products
of fermentation. Previous studies in mice demonstrated that
bioactive compounds released in milk fermented by
Lactobacillus helveticus R389 contribute to its
immunoenhancing and antitumour properties. The aim of the
present work was to study the effects of the consumption of milk
fermented by L. helveticus R389 or its proteolytic-deficient
variant,  L. helveticus L89, on a murine hormone-dependent
breast cancer model.
Methods Mice were fed with milk fermented by L. helveticus
R389 or L. helveticus L89, during 2 or 7 days. The tumour
control group received no special feeding. At the end of the
feeding period, the mice were challenged by a subcutaneous
injection of tumour cells in the mammary gland. Four days post-
injection, the mice received fermented milk on a cyclical basis.
The rate of tumour development and the cytokines in serum,
mammary gland tissue and tumour-isolated cells were
monitored. Bcl-2-positive cells in mammary glands and cellular
apoptosis in tumour tissue were also studied.
Results Seven days of cyclical administration of milk fermented
by either bacterial strain delayed or stopped the tumour
development. Cytokines demonstrated that L. helveticus R389
modulated the immune response challenged by the tumour. IL-
10 and IL-4 were increased in all the samples from this group. In
comparison with the tumour control, all test groups showed a
decrease of IL-6, a cytokine involved in oestrogen synthesis.
Seven days of cyclical feeding with milk fermented by L.
helveticus  R389 produced an increase in the number of
apoptotic cells, compared with all other groups.
Conclusion This study demonstrated that 7 days of cyclical
administration of milk fermented by both strains of L. helveticus
diminishes tumour growth, stimulating an antitumour immune
response. Compounds released during milk fermentation with L.
helveticus R389 would be implicated in its immunoregulatory
capacity on the immune response in mammary glands and
tumour, which were correlated with the cytokines found at the
systemic level. The milk fermented by L. helveticus R389 was
able to modulate the relationship between immune and
endocrine systems (by IL-6 diminution), which is very important
in oestrogen-dependent tumour and induced cellular apoptosis.
Introduction
Considerable advances have been made in recent years
towards an understanding of the molecular factors involved in
breast cancer development, but for women in most Western
countries breast cancer still remains a major cause of death.
There are genetic and environmental factors that increase the
chances of breast cancer, and the most common breast can-
cer types are oestrogen dependent. Some factors, such as
diets rich in cultured dairy products, may inhibit the growth of
many types of cancer, including breast tumours and the most
investigated to date, colon cancer.
Live microbial feed supplements added to beneficially affect
the host animal are known as probiotics [1]. Lactic acid bacte-
ria (LAB) are the microorganisms most commonly used as pro-
biotics to favour some biological functions in the host. LAB
have been shown to exert effects on the immune system of the
consumer and to increase the resistance to neoplasia and
infections [2]. Consumption of LAB and milks fermented by
ELISA = enzyme-linked immunosorbent assay; IFN-γ = interferon gamma; IL = interleukin; LAB = lactic acid bacteria; PBS = phosphate-buffered 
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them can increase the systemic immune response (macro-
phage function and number of immunoglobulin-secreting
cells) [3,4] as well as increase the local immune responses in
the mucosal areas (IgA-positive cells in the intestine, bronchus
and mammary glands [5]). For these and other reasons, there
is a steady increase in the consumption of fermented dairy
products (i.e. yoghurt and other fermented milks) containing
viable LAB.
Immunostimulation by fermented milks as a mean of keeping
the host immune system in a permanent state of alert has been
shown to successfully prevent different cancers [4,6,7]. Ben-
eficial effects of fermented products in colon cancer preven-
tion have been widely reported [8,9]. Studies carried out with
an animal model of colon cancer showed inhibition of the
tumour through yoghurt feeding, demonstrating that yoghurt
modulated the immune system response and exerted its anti-
tumour activity through its anti-inflammatory capacity [10,11].
This effect was observed by long-term cyclic yoghurt con-
sumption, which inhibited promotion and progression of the
experimental intestinal tumour [12].
In addition to LAB, fermented milks can possess other non-
bacterial components produced during fermentation that con-
tribute to immunogenicity and to other properties like their
antitumour activities.
Matar and colleagues [13] have reported different roles and
functions of biologically active peptides released from fer-
mented milks. Peptides and free fatty acids released during
fermentation were shown to increase the immune response. In
this way, peptidic fractions liberated during milk fermentation
with  Lactobacillus helveticus R389 stimulated the immune
system and inhibited the growth of an immunodependent fib-
rosarcoma in a mouse model [14]. The peptidic profiles of milk
proteins were significantly different after fermentation by LAB,
suggesting that microbial proteolysis could be a potential
source of bioactive peptides [15]. Milk fermented with L. hel-
veticus R389, a bacterium with high protease and peptidase
activity, exerted an antimutagenic effect, while a mutant strain
(L. helveticus L89) deficient in proteolytic activity did not [16].
In a similar way, milk fermented with the proteolytic strain
increased the number of IgA-positive cells in the small intes-
tine as well as in the bronchus of mice, but fermented milk
obtained with the proteolytic-deficient mutant strain did not
show the same in vivo results [6].
Fractions separated by dialysis from yoghurt showed tumour
inhibition in in vivo murine assays [17]. Biffi and colleagues
[18] studied the direct effect of milk fermented by five bacteria
species (Bifidobacterium infantis,  Bifidobacterium bifidum,
Bifidobacterium animalis,  Lactobacillus acidophilus, and
Lactobacillus paracasei) on the growth of a breast cancer cell
line, and reported that the antiproliferative effect was not
related to the presence of bacteria in the fermented milk. This
study suggested the potentiality offered by fermented milks as
producers of compounds with antiproliferative activity useful in
the prevention and therapy of solid tumours like breast cancer.
The aim of the present work was to study the effects of the
consumption of milk fermented by L. helveticus R389 or its
proteolytic deficient variant, L. helveticus L89, on a murine hor-
mone-dependent breast cancer model, studying the systemic
and local immune responses in the mammary glands and
tumours.
Materials and methods
Animals and diets
BALB/c mice from Charles River Laboratories (Montreal, QC,
Canada), weighing 19–21 g were separated into five experi-
mental groups: the tumour control group, where the mice
received an injection with the tumour cells; the P(+) 2d group,
where the mice were fed with milk fermented by L. helveticus
R389, proteolytic variant, for two consecutive days (basal 2
days), were injected with the tumour cells, and were then fed
cyclically every 5 days with the fermented milk until day 28; the
P(-) 2d group, which was the same as the P(+) 2d group
except the mice were fed milk fermented with L. helveticus
L89, the deficient proteolytic variant, instead of R389; the P(+)
7d group, where the mice were fed with milk fermented by L.
helveticus R389 for seven consecutive days (basal 7 days),
were injected with the tumour cells, and were then fed cycli-
cally every 5 days, with the same fermented milk; and the P(-)
7d group, which was the same as the P(+) 7d group except
that the mice were fed milk fermented with L. helveticus L89
instead of L. helveticus R389.
All groups contained 25–30 mice that were fed with a bal-
anced diet ad libitum.
Milk fermentation
Nonfat, dried, low-heat-grade milk without added vitamins A
and D (Dairytown Products Ltd, Sussex, NB, Canada) was
rehydrated (12% wt/vol) and autoclaved (115°C for 15 min) to
make the inoculums. The prepared milk was inoculated with L.
helveticus R389 (2% vol/vol) and incubated at 37°C during
17 hours. Yeast extract (0.4%) was added to the milk used to
grow L. helveticus L89 before autoclaving. This milk was then
inoculated with L. helveticus L89 (2% vol/vol) and incubated
at 37°C for 17 hours. Both fermented milks had a concentra-
tion of 1 × 109 colony-forming units/ml at the end of the fer-
mentation period.
The inoculums were added to rehydrated milk prepared in the
same manner (2% vol/vol) in 12% milk or 12% milk plus 0.4%
yeast extract to start the milk fermentation.
The extent of milk protein proteolysis was evaluated using the
o-phthaldialdehyde test [19].Available online http://breast-cancer-research.com/content/7/4/R477
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Tumour induction and the feeding procedure
The ATCC tumoural cell line 4T1 was used to induce breast
tumour growth. Each mouse was challenged by a single sub-
cutaneous injection (0.5 ml) of tumour cells (1.4 × 104 cells/
ml) in the upper right mammary gland.
The experimental groups – P(+) 2d, P(-) 2d, P(+) 7d and P(-)
7d – were given a diet supplemented with milks fermented by
L. helveticus R389 or L. helveticus L89 for two or seven con-
secutive days. At the end of each feeding period the mice
were injected with the tumour cells in the same way that the
tumour control animals were. Four days after the tumour injec-
tion, fermented milks were added again to the diet during two
or seven consecutive days (depending on the group), followed
by a 5-day break, and then again fermented milk feeding for 2
or 7 days. Feeding was given in this manner cyclically until the
end of the experimentation (28 days after tumour induction).
Obtaining the samples
The following samples were obtained from each group: basal
sample (day 0), after 2 or 7 days of fermented milk feeding,
and 12, 18, 22 or 28 days after tumour cell inoculation. Mice
were anaesthetized intraperitoneally using a mix of ketamine
hydrocholoride (Bioniche Animal Health Canada Inc, Ontario,
Canada), 100 µg/g body weight, and xylazine hydrochloride
(Sigma, St Louis, MO, USA), 5 µg/g body weight. Blood sam-
ples were obtained by cardiac punction. For the basal sample,
and 12 days after tumour cells injection, mammary glands
were removed. In the subsequent samples the tumour was
also removed.
To obtain serum, blood was incubated at 37°C during 3 hours
and was centrifuged at 1000 × g for 10 min. The serums were
stored at -20°C until they were used for cytokine
measurement.
ELISA assays of serum samples
To determine the concentration of the different cytokines
(tumour necrosis factor alpha [TNF-α], interferon gamma [IFN-
γ], IL-10, IL-4 and IL-6) in serum, the BD OptEIA™ mouse
cytokine ELISA kits from BD Bioscience (San Diego, CA,
USA) were used. The results are expressed as concentration
of each cytokine in serum (pg/ml).
Cytokine-producing cell determination in histological 
sections
Mammary gland tissue sections (4 µm) from each group were
used for immunofluorescence assays. Tissues were prepared
for histological evaluation, were fixed in formaldehyde, were
dehydrated using a graded series of ethanol and xylene sub-
stitute, and were embedded in paraffin.
Cytokines and Bcl-2-positive cells were detected by indirect
immunofluorescence following the technique described by de
Moreno de LeBlanc and colleagues [11]. Rabbit anti-mouse
TNF-α, IFN-γ, IL-10, IL-6 and IL-4 (Peprotech, Inc., Rocky Hill,
NJ, USA) polyclonal antibodies (diluted in saponin-PBS) were
applied to the sections for 75 min at room temperature (21°C).
The sections were then treated with a dilution of goat anti-rab-
bit antibody conjugated with fluorescein isothiocyanate (Jack-
son Immuno Research Labs Inc., West Grove, PA, USA).
Bcl-2 protein was measured using the same protocol with a
diluted hamster anti-mouse Bcl-2 monoclonal antibody
(PharMingen; Becton Dickinson Co., San Diego, CA, USA)
and a dilution of the rabbit anti-Syrian hamster antibody conju-
gated with fluorescein isothiocyanate (Jackson Immuno
Research Labs Inc.). The number of fluorescent cells was
counted in 30 fields of vision as seen at 1000 × magnification
using a fluorescence light microscope. The results were
expressed as number of positive cells in 10 fields of vision as
seen with 1000 × magnification using a fluorescence light
microscope.
Isolation of mononuclear cells from the breast tumour
Tumours of three mice from each group were removed 18, 22
and 27 days after tumour inoculation and were washed with
Hank's balanced saline solution (Sigma) with 4% foetal bovine
serum. The cells were separated mechanically and incubated
in 0.05% protease/collagenase (Sigma) solution in RPMI
1640 medium (Sigma) with added 10% foetal bovine serum at
37°C and agitated with a magnetic bar for 40 min. The cells
collected from supernatant were washed with RPMI 1640
medium. The immune cells were concentrated using a percoll
gradient (100% to 55% to 30%), were centrifuged at 800 × g
for 30 min, and were recovered from the layer between 100%
and 55%. Cells were adjusted at 4 × 106 to 5 × 106 cells/ml
in RPMI 1640 medium. Cell suspensions (20 µl) were placed
in each well of an immunofluorescence slide and were fixed
with formalin (ICC fixation buffer, PharMingen; Becton Dickin-
son Biosciences, San Diego, CA, USA).
Cytokine determination in isolated cells
TNF-α, IL-4, IL-10, IL-6 or IFN-γ were determined in the fixed
cells. They were incubated with 1% blocking solution of
bovine serum albumin/PBS, were washed with PBS and were
incubated with normal goat serum (diluted 1/10). The activity
of the endogenous peroxidase was blocked with H2O2/meth-
anol solution. The cells were then incubated with avidin-block-
ing and biotin-blocking solutions (avidin/biotin blocking kit;
Vector Labs, Inc., Burlingame, CA, USA) to block endogenous
avidin and biotin. The cells were incubated with rat anti-mouse
TNF-α, IFN-γ, IL-10 or IL-4 polyclonal antibody (diluted in dilu-
ent ICC cytokine buffer; PharMingen, Becton Dickinson Bio-
sciences), were washed with PBS, and were incubated with a
biotin-conjugated goat anti-rat immunoglobulin-specific poly-
clonal antibody (PharMingen; Becton Dickinson Biosciences).
Biotinylated anti-mouse IL-6 polyclonal antibody (PharMingen;
Becton Dickinson Biosciences) was used to determine IL-6-
positive cells. Vectastain Elite ABC solution (Vector Labs) wasBreast Cancer Research    Vol 7 No 4    de Moreno de LeBlanc et al.
R480
added to cells and they were incubated with a DAB kit (Vector
Labs). The results were expressed as percentage (number of
positive cells in 100 cells counted at 1000 × magnification).
Apoptosis determination
Apoptosis was evaluated by the presence of DNA breaks,
detected in the paraffin cuts using the Apoptosis Detection
System kit, Fluorescein (Promega, Madison, WI, USA). The
fragmented DNA of apoptotic cells was measured by incorpo-
ration of fluorescein-12-dUTP at the 3'-OH ends of DNA using
terminal deoxynucleotidyl transferase, which forms a polymeric
tail via the principle of the Terminal deoxynucleotidyl Trans-
ferase Biotin-dUTP Nick End Labeling (TUNEL) assay. The flu-
orescein-12-dUTP nick end-labelled DNA was visualized
directly by fluorescence microscopy. Cells were defined as
apoptotic if the whole nuclear area of the cell was stained
fluorescent.
Apoptosis was expressed as the number of apoptotic cells 10
ten fields with 1000 × magnification, using a fluorescence
microscope with a standard fluorescent filter.
Statistical analysis
Comparisons were performed using the software package
SigmaStat (SPSS, Chicago, IL, USA).
Comparisons of multiple means were accomplished by one-
way analysis of variance followed by a 150 Tukey's post-hoc
test. P < 0.05 was considered significant. Unless otherwise
indicated, all values are the means of three independent trials
± standard deviation.
Results and discussion
The intestine is the first area of study to assay different prop-
erties of probiotics that enter the host by the oral route. This
host contains the 'common' mucosal immune system, which
ensures that all mucous membranes are furnished with a wide
spectrum of secretory antibodies [20]. Both B cells and T cells
can migrate from Peyer's patches, found in the small intestine,
to mucosal membranes of the respiratory, gastrointestinal and
genitourinary tract, as well as to exocrine glands such as the
lacrimal glands, salivary glands, mammary glands and pros-
tatic glands [21].
Lactobacillus casei CRL 431 administered orally was able to
stimulate the IgA cycle, increasing IgA-positive cells not only in
the intestine, but also in the bronchus and mammary gland tis-
sues [5].
Previous studies performed in our laboratory showed different
effects when mice were fed with milk fermented by L. helveti-
cus R389 or its proteolytic deficient variant, L. helveticus L89
[6]. Mice fed with the L. helveticus R389 showed stimulation
of the mucosal immune system. Also, it was observed that 2
and 7 days of feeding with this bacterial strain were optimal to
stimulate the mucosal system of mice (data not shown). This
strain was also able to prevent the growth of transplantable fib-
rosarcoma in mice [6]. These previous works led us to study
the effect of L. helveticus R389 on the growth of breast can-
cer in an animal model, comparatively with the proteolytic-defi-
cient strain L. helveticus L89.
Tumour growth
In the present work, mice were fed cyclically following a previ-
ous model of feeding with yoghurt to inhibit a colon tumour in
mice, in which yoghurt feeding showed a modulation of the
immune response in intestine [11]. Here we showed that mice
receiving a 2-day cyclical fermented milk feeding did not show
significant differences in tumour volume, compared with the
tumour control group (Fig 1). Seven-day cyclical administra-
tion of both bacterial strains delayed or stopped tumour devel-
opment, as compared with the control group (Fig. 1). There
were no significant differences between both bacterial strains
used in milk fermentation cyclical feeding for either 2 or 7 days
(Fig. 1). Either the LAB themselves or some substances
released during milk fermentation were responsible for this
observed effect: mice fed only with milk (or with milk plus 0.4%
yeast extract) did not show differences in the tumour size com-
pared with the control (data not shown)
Determination of cytokine levels in blood serum
The influence of immune cells in breast cancer development
has been reported in different models, but to our knowledge
no published reports have studied the in vivo immunomodula-
tory effects of LAB and their relationship with mammary glands
or breast cancer. Cytokines have been shown to regulate oes-
trogen synthesis in breast tumours, stimulating research into
these important molecules. In this work, cytokines were
Figure 1
Rate of tumour growth Rate of tumour growth. Results are expressed as the volume (cm3) of 
the tumour for each mouse of different groups (tumour control group, 
black circle and line; P(+) 2d group, grey square and dark grey line; P(-
) 2d group, white triangle and black broken line; P(+) 7d group, black 
diamond and lines of points; P(-) 7d group, grey triangle and light grey 
broken lines) with the tendency line for each group.Available online http://breast-cancer-research.com/content/7/4/R477
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assayed in different samples to have a spectrum at a systemic
level, and to measure the local response in mammary glands
or tumours to study the effect of our fermented milks on the
immune response.
TNF-α is a cytokine with various functions such as proinflam-
matory pathway properties, tumour necrosis pathway proper-
ties, and apoptosis pathway properties [22,23]. TNF-α levels
increased in the serum as a function of time as did the tumour
volume in the control group (Fig. 2a). Mice from both 2-day
groups showed increases of this cytokine in serum at day 12
(234 ± 14 pg/ml, 206 ± 38 pg/ml and 207 ± 24 pg/ml, for the
P(+) 2d, P(-) 2d and tumour control groups, respectively).
TNF-α levels remained constant after day 12. Mice that
received 7 days of cyclical feeding with milk fermented with L.
helveticus R389 or L. helveticus L89 showed a significant
increase (P < 0.05) of TNF-α in the basal sample (207 ± 43
pg/ml and 256 ± 51 pg/ml for the P(+) 7d group and the P(-)
7d group, respectively), compared with the tumour control
group (42 ± 2 pg/ml). This increase before tumour induction
could be related to the decrease in the tumour growth in the
mice from these groups. The P(+) 7d group maintained a TNF-
α concentration near the basal level throughout the trial, show-
ing a regulation of this cytokine, whereas the P(-) 7d group
showed increased TNF-α in the final sample, similar to the
control group (530 ± 71 pg/ml and 603 ± 106 pg/ml for 28
days, in the P(-) 7d group and control group, respectively).
These results (the TNF-α increase) showed a typical immune
response to the tumour [24].
IFN-γ is a cytokine related to the inflammatory response, but it
was also reported as a key effector molecule in the immune
response against solid cancers. Tumour infiltrating lym-
phocytes from ovarian tumours released this cytokine upon
challenge with MICA-positive tumour cells [25]. In our study,
IFN-γ levels varied in the different groups as a function of time
(Fig. 2b).
IL-6 is a cytokine implicated in oestrogen synthesis [26], a hor-
mone that the tumour needs for growth. It is also a proang-
iogenic factor [27], supporting the growth of new blood
vessels that are essential for tumour growth. The three groups
in which the tumour grew at a faster rate showed elevated lev-
els of IL-6 (Fig. 2c). The P(+) 7d and P(-) 7d groups did not
show increased levels of this cytokine throughout the time of
the study, suggesting that this IL-6 decrease is involved in one
of the mechanisms for the delay of tumour growth.
IL-10 and IL-4 are known as regulatory cytokines, associated
with activated Th2 lymphocytes [22]; IL-10 can also be pro-
duced by other cell populations such as macrophages and
dendritic cells. In different experimental models, TNF-α and IL-
10 were demonstrated to have opposite effects [28]. The bal-
ance between TNF-α and IL-10 could modulate the effector
function of macrophages and cellular apoptosis. IL-4 plays a
significant role in controlling both cell growth and modulation
of the immune response [29]. This cytokine has antagonist
functions to IFN-γ and appears to possess certain anti-inflam-
matory properties; IL-4 can inhibit the production of several
Figure 2
Effect of tumour injection and fermented milk feeding on the serum cytokines Effect of tumour injection and fermented milk feeding on the serum cytokines. (a) Tumour necrosis factor alpha (TNFα), (b) interferon gamma (IFNγ), 
(c) IL-6, (d) IL-4 and (e) IL-10. Results are expressed as the mean concentration of each cytokine (pg/ml) ± standard deviation. Means for each 
cytokine without a common letter differ significantly (P < 0.05).Breast Cancer Research    Vol 7 No 4    de Moreno de LeBlanc et al.
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proinflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α
[22]. There was a significant increase (P < 0.05) in IL-10 and
IL-4 concentrations in the serum obtained from the P(+) 7d
group in relation to the tumour control group, beginning at day
18 after tumour injection (Fig. 2e), which could explain the reg-
ulation of the immune response observed for TNF-α and IL-6
in these animals. This regulatory response was not observed
in the P(-) 7d group. Mice from the P(+) 2d group showed
increases for IL-10 concentrations in serum compared with
the control, but the levels obtained were significantly lower (P
< 0.05) than the P(+) 7d group. The P(-) 2d group showed
increases of IL-10 compared with the tumour control group,
but not compared with the other groups described. These
results concur with the development of the tumour observed
in these groups of mice.
IL-4 increased in all test groups in the basal sample, in com-
parison with the control group (18 ± 1 pg/ml). The P(+) 7d
group showed the largest increases throughout the study (Fig.
2d).
Study of cytokine-positive cells in mammary gland 
tissues
Differences were observed with regard to the systemic levels
of cytokines between the groups where the tumour grew and
those where it did not; it was possible to observe a regulation
of the immune response in the P(+) 7d group, but not in the
P(-) 7d group.
The study of cytokine-positive cells in mammary glands
allowed an understanding of the local cell response, after mice
were fed with fermented milk as well as after tumour injection,
in the tumour control group and different test groups.
TNF-α-positive cells in mammary glands showed very similar
patterns to those obtained for this cytokine in serum. TNF-α-
positive cells increased in the tumour control group through-
out the tumour growth. The same observation was seen in the
P(+) 2d and P(-) 2d groups (Fig. 3a). This cytokine increased
in the P(+) 7d and P(-) 7d groups 12 days after tumour injec-
tion (13 ± 5 cells / 10 fields and 18 ± 5 cells / 10 fields,
respectively), and the number of positive cells remained con-
stant afterwards (Fig. 3a).
IFN-γ-positive cells increased in the tumour control group
throughout the trial. The P(+) 2d and P(-) 2d groups showed
similar values to the control group at the end of the experimen-
tal period (27 ± 3 cells / 10 fields, 22 ± 4 cells / 10 fields and
24 ± 5 cells / 10 fields for the P(+) 2d, P(-) 2d and control
groups, respectively). Seven days of cyclical feeding, inde-
pendent of the bacterial strain used, maintained the number of
positive cells for this cytokine; however, a significant decrease
was observed in the final samples compared with the other
groups (14 ± 3 cells / 10 fields and 13 ± 4 cells / 10 fields for
the P(+) 7d group and the P(-) 7d group, respectively) (Fig.
3b).
The IL-6-positive cell number was constant and similar in all
groups until 18 days after tumour injection. This observation
can be explained because this cytokine is related to the syn-
thesis of oestrogen in the mammary gland, a hormone that this
tumour cell line needs for proper growth. Eighteen days after
tumour cell injection, these cytokine-positive cells increased in
the control, P(+) 2d and P(-) 2d groups, whereas both the
P(+) 7d and P(-) 7d groups showed no differences in the
number of IL-6-positive cells, showing significantly lower num-
bers in relation to the other groups (Fig. 3c).
IL-10-positive cells increased in the control group after 12
days of tumour injection (11 ± 3 cells / 10 fields) compared
with the basal number (6 ± 2 cells / 10 fields), and remained
constant throughout the study (Fig. 3e). Mice fed with L. hel-
veticus R389 had increased numbers of IL-10-positive cells
throughout the time of the entire study, but only the P(+) 7d
group showed significantly higher numbers (P < 0.05) com-
pared with the tumour control group on days 18 and 22 (25 ±
5 cells / 10 fields and 22 ± 3 cells / 10 fields at 18 days, and
14 ± 6 cells / 10 fields and 11 ± 3 cells / 10 fields at 22 days
for the P(+) 7d group and the control group, respectively; see
Fig. 3e). This cytokine can be related to the regulation of the
other cytokines observed in this group, where increases in
TNF-α-positive and IFN-γ-positive cells in mammary glands
were observed. This was not the case with the P(-) 7d group,
which did not show a significant increase of IL-10-positive
cells compared with the tumour control group.
The number of IL-4-positive cells followed the same pattern as
the IL-10-positive cells (Fig. 3d): significant increases (P <
0.05) were observed in the final samples of the P(+) 2d and
P(+) 7d groups (21 ± 5 cells / 10 fields, 22 ± 4 cells / 10
fields and 15 ± 5 cells / 10 fields for the P(+) 2d, P(+) 7d and
control groups, respectively) compared with the control.
Determination of cytokines in tumour-infiltrative cells
Breast tumour tissue contains malignant epithelial cells, stro-
mal cells, adipocytes, lymphocytes and macrophages. The role
of tumour-infiltrating immune cells in antitumour immunity, as
well as their potential for cancer immunotherapy, has been
investigated extensively [30,31]. Lymphocytes and macro-
phages invade the tumour in response to cytokines such as IL-
8 and macrophage chemoattractant protein 1. These lym-
phocytes and macrophages produce IL-6, IL-6 soluble recep-
tor, and TNF-α. IL-6 is also produced by stromal cells, and
TNF-α is also produced by adipocytes. IL-6 is able to stimulate
activity of aromatase, an enzyme related to the synthesis of
oestrogen from androgens in malignant cells and stromal cells.
IL-6 acts through its receptor on malignant cells.Available online http://breast-cancer-research.com/content/7/4/R477
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TNF-α showed differences in the isolated cells compared with
the other samples (serum and mammary glands). It has previ-
ously been reported that cytokines produced by tumour-infil-
trating immune cells play an important role in the antitumour
response [32]. The positive cells for this cytokine increased in
the groups fed with fermented milk where the tumour growth
was delayed (the P(+) 7d and P(-) 7d groups), showing that
an induction of the production of this cytokine by fermented
milk may be playing a biological role in the induction of cellular
apoptosis. TNF-α-positive cells increased in the P(+) 7d and
P(-) 7d groups 22 days after tumour injection (31 ± 4 cells /
100 and 47 ± 10 cells / 100), but on the last sample (day 27)
the number of positive cells did not differ significantly with the
control group and the 2-day groups. The same observation
was shown with the IFN-γ-positive cells (Table 1).
IL-10 is a regulatory cytokine that can be released by tumour-
infiltrating immune cells such as macrophages and lym-
phocytes. IL-10(+) cell numbers decreased in both the control
and the P(+) 2d groups throughout the time of the entire study.
The IL-10(+) cells increased significantly (P  < 0.05) in
tumours from P(-) 2d and P(-) 7d groups at 22 days after
tumour injection, as compared to the control (18 ± 2 cells /
100, 16 ± 6 cells / 100 and 6 ± 2 cells / 100 for P(-) 2d, P(-)
7d and control, respectively). P(+) 7d was the group with the
highest number of IL-10(+) cells (29 ± 7 cells / 100) at 22
days. It is possible to observe another increases of these cells
in mice from P(+) 7d group, such as were observed in the
other samples (serum and mammary gland tissues), probably
to regulate the proinflammatory cytokines (TNF-α and IFN-γ)
produced. IL-4-positive cells were variable in all groups, and
Figure 3
Cytokine-positive cells in mammary glands Cytokine-positive cells in mammary glands. Positive cells for each cytokine were counted in histological sections from mammary glands of the 
tumour control group (black bars), the P(+) 2d group (white bars), the P(-) 2d group (diagonal lined bars), the P(+) 7d group (grey bars) and the P(-
)7d group (horizontal lined bars). (a) Tumour necrosis factor alpha (TNFα), (b) interferon gamma (IFNγ), (c) IL-6, (d) IL-4, (e) IL-10 and (f) Bcl-2. Val-
ues are means ± standard deviation for n = 5. Means for each cytokine without a common letter differ significantly (P < 0.05).Breast Cancer Research    Vol 7 No 4    de Moreno de LeBlanc et al.
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no significant increases were observed. All mice fed with fer-
mented milk showed decreases in the number of IL-6 (+) cells
compared to the tumour control group. This shows a protec-
tive effect of the LAB in this oestrogen-dependent tumour, due
mainly to the decrease in IL-6. Inter-group differences were
observed. After 18 days, P(-) 7d increased these positive cells,
and the values were similar to P(+) 2d and P(-) 2d. Only P(+)
7d maintained the number of IL-6 (+) cells significantly lower
than the other test groups in all the samples, showing once
again the best antitumour response.
Apoptosis and Bcl-2-positive cell determination
The mechanisms of apoptosis (or programmed cell death) in
the inhibition of tumour progression are well documented [33].
Apoptosis is a complex and active cellular process in which
individual cells are triggered to undergo self-destruction in a
manner that will neither injure neighbouring cells nor elicit an
inflammatory reaction. The balance between cell proliferation
and cell death is important to maintain equilibrium in different
tissues, and a disturbance in this balance may lead to tumour
development [34] since the disruption of this type of regulation
is a characteristic of tumours.
Considering that cytokines such as TNF-α could be involved
in certain apoptotic pathways [23], and that an enhancement
of this cytokine was observed in our experimental model,
apoptosis induction was studied (Table 2). The P(+) 2d and
P(-) 2d groups showed a significant increase (P < 0.05) in the
number of apoptotic cells at day 18, in relation to the control
and other test groups. In mice from the P(+) 7d group, a sig-
nificant increase was observed in the number of apoptotic
cells (P < 0.05), compared with all the other groups, begin-
ning at day 22. The increase in cellular apoptosis in the mice
of the P(+) 7d group could play a role in the delay of the
tumour growth.
Bcl-2 protein is a measure of cell survival due to its anti-apop-
totic activity [23], which can be used to stimulate the growth
of tumour cells. The increase of cellular apoptosis in mice from
the group fed with fermented milk led us to study the Bcl-2
protein.
Significant differences between the groups were not observed
when Bcl-2-positive cells were studied in tumour tissues (data
not shown), but differences were seen in mammary gland tis-
sues. Bcl-2-positive cells increased significantly (P < 0.05) in
the final sample for the control group as compared with the
basal sample for that group (33 ± 5 cells / 10 fields and 22 ±
4 cells / 10 fields at day 27 and the basal sample, respectively;
Fig. 3f). The P(+) 7d and P(-) 7d groups showed significant
decreases of Bcl-2-positive cells in mammary glands com-
pared with the tumour control in the same period. These
Table 1
Cytokine-positive cells isolated from the tumour
Experimental group Sample (days) Cytokine
Tumour necrosis 
factor alpha
Interferon gamma IL-6 IL-4 IL-10
Tumour control 18 24 ± 2ae 22 ± 6ac 29 ± 2a 25 ± 5a 18 ± 2ae
22 12 ± 4bcd 17 ± 3ad 25 ± 3a 17 ± 4ad 6 ± 2b
27 13 ± 1bcd 12 ± 4b 23 ± 4abd 10 ± 3ce 8 ± 2b
P(+) 2d 18 21 ± 3ce 26 ± 8cde 12 ± 3d 11 ± 1bcde 19 ± 4a
22 9 ± 1d 10 ± 2b 8 ± 1cd 12 ± 2bcde 7 ± 3bc
27 11 ± 3bd 12 ± 4bd 17 ± 3d 10 ± 1ce 9 ± 2bc
P(-) 2d 18 14 ± 6bcd 14 ± 5abd 10 ± 3c 7 ± 2e 9 ± 4bc
22 19 ± 4bce 13 ± 4ab 16 ± 1bd 13 ± 5bcde 18 ± 6ae
27 12 ± 2bd 12 ± 2b 17 ± 2bd 7 ± 2e 8 ± 2bd
P(+) 7d 18 22 ± 7ac 20 ± 2ae 4 ± 2c 15 ± 5dbc 14 ± 3ace
22 31 ± 4a 30 ± 5c 9 ± 2c 8 ± 1e 29 ± 7
27 13 ± 1bcd 17 ± 5abe 4 ± 1c 6 ± 1e 12 ± 2eb
P(-) 7d 18 12 ± 2bcd 14 ± 1b 4 ± 1c 12 ± 3bcde 13 ± 6acde
22 53 ± 15 44 ± 6 17 ± 3bd 12 ± 3bcde 16 ± 4ace
27 11 ± 4bd 24 ± 5ac 13 ± 4d 9 ± 1ce 9 ± 3bcd
Results are expressed as means ± standard deviation of cytokine-positive cells for each 100 counted cells (cells/100). Means for each cytokine 
without a common letter differ significantly (P < 0.05).Available online http://breast-cancer-research.com/content/7/4/R477
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decreases were significant for both groups in the final sample
(16 ± 3 cells / 10 fields, 16 ± 4 cells / 10 fields and 33 ± 5
cells / 10 fields for the P(+) 7d, P(-) 7d and control groups,
respectively; Fig. 3f) and concur with the apoptosis results.
Conclusion
Numerous mechanisms in which the immune system plays a
role can be involved in the antitumour activity of fermented
milks, which could be mediated by the bioactive substances
released during fermentation and by the microorganisms used
as starter cultures.
Our studies using a model of breast cancer in mice demon-
strated that 7 days of cyclical feeding with milk fermented by
L. helveticus R389 or L. helveticus L89 delayed tumour devel-
opment. This effect was related principally to a decrease in IL-
6, a cytokine implicated in the synthesis of oestrogen in both
normal and tumour-invaded breast. L. helveticus R389, a
strain with high proteolytic activity, has been selected for
future studies because of its capacity to modulate the immune
response. Milk fermented by this LAB induced not only a
decrease of IL-6, but also an increase of regulatory cytokines,
principally IL-10, and also induced cell apoptosis in the
tumour. This observation allows us suggest that substances
released in this fermented milk, possibly peptides due to the
high proteolytic activity of the bacterial strain, could be related
to the regulatory response observed with this fermented milk,
which was not observed with the milk fermented by L. helveti-
cus L89 (proteolytic-deficient variant).
This is the first report of an in vivo study demonstrating the
possible mechanisms by which LAB and fermented milks can
influence the activity of the infiltrative immune cells in mam-
mary glands, and also to delay or even stop a breast tumour.
This study has demonstrated the immunoregulatory capacity
of milk fermented by L. helveticus R389 on the immune
response in mammary glands and tumour, as well as the cor-
relations with the cytokines found at a systemic level. The milk
fermented by L. helveticus R389 was able to delay tumour
growth by its immunoregulatory capacity, and we demon-
strated that this fermented milk was able to modulate the rela-
tionship between immune and endocrine systems by IL-6
decrease, which is very important in oestrogen-dependent
tumours, and by induction of cellular apoptosis.
Research is currently in progress into the antitumour/immu-
nomodulating properties of substances released during milk
fermentation by this highly proteolytic LAB, and their effects on
breast cancer development.
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